SCHEMBL20158604

SCHEMBL20158604

CCN1CCC(Oc2ncc(Cl)cc2F)CC1

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
FPR2 P25090 3/20 0.53
PROKR1 Q8TCW9 3/20 0.53
IP6K1 Q92551 4/20 0.45
ACACB O00763 2/20 0.42
HRH3 Q9Y5N1 2/20 0.41
RET P07949 1/20 0.41
SGK1 O00141 3/20 0.40
KDM4E B2RXH2 1/20 0.39
MEN1 O00255 1/20 0.39
ALDH1A1 P00352 1/20 0.39
KMT2A Q03164 1/20 0.39
AXL P30530 1/20 0.38
TYRO3 Q06418 1/20 0.38
MERTK Q12866 1/20 0.38
KCNH2 Q12809 1/20 0.36
SCD O00767 1/20 0.36
WEE1 P30291 1/20 0.35
PLK1 P53350 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20069587 0.85 FPR2 (0.58) FPR2PROKR1IP6K1ACACBRET
SCHEMBL20147428 0.81 FPR2 (0.53) FPR2PROKR1IP6K1ACACBHRH3
SCHEMBL20205806 0.79 HRH3 (0.45) HRH3RETWEE1PLK1
SCHEMBL16657599 0.76 FPR2 (0.46) FPR2PROKR1IP6K1ACACB
Hydrochloric Acid SCHEMBL29947153 0.74 FPR2 (0.46) FPR2PROKR1IP6K1ACACB
SCHEMBL15536268 0.74 GPR119 (0.50) FPR2PROKR1
SCHEMBL29947210 0.74 GPR119 (0.50) FPR2PROKR1
SCHEMBL29947136 0.72 FPR2 (0.45) FPR2PROKR1IP6K1RETSCD
SCHEMBL18202730 0.71 HRH3 (0.44) HRH3KDM4EMEN1ALDH1A1KMT2A
SCHEMBL19941066 0.71 FPR2 (0.63) FPR2PROKR1ACACB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10172845-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors ARRAY BIOPHARMA INC. (US) 2019-01-08 US disclosed
US-20180134703-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2018-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10172845-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors RET, BRAF, RAF1 FPR2 3689/4885PROKR1 438/4885IP6K1 1146/4885
US-20180134703-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, BRAF, RAF1 FPR2 3689/4885PROKR1 438/4885IP6K1 1146/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.